一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Amivantamab IV；Amivantamab SC；Lazertinib；Doxycycline；Minocycline；Clindamycin；Chlorhexidine；Noncomedogenic skin moisturizer；Ruxolitinib；Tacro，当前状态为研究进行中，已停止招募。登记地点显示中国常州、Chengdoucun、成都、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Amivantamab IV；Amivantamab SC；Lazertinib；Doxycycline；Minocycline；Clindamycin；Chlorhexidine；Noncomedogenic skin moisturizer；Ruxolitinib；Tacrolimus；Zinc gluconate；Propranolol；Timolol；Clobetasol · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Changzhou No 2 Peoples Hospital · 常州
- West China Hospital · Chengdoucun
- Sichuan Cancer Hospital · 成都
- The First Affiliated Hospital Sun Yat sen University · 广州
- The First Affiliated Hospital Zhejiang University School of Medicine · 杭州
- Harbin medical university cancer hospital · 哈尔滨
- Huizhou Municipal Central Hospital · 惠州
- Zhongda Hospital Southeast University · 南京
- Fudan University Shanghai Cancer Center · 上海
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for
- * Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certif
- * A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indica
- * Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion coho
- * Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care \[SoC\]) Grade \>=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06120140；登记信息更新于 2026-09-25。